Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IMA 901

Drug Profile

IMA 901

Alternative Names: IMA-901; Renal cancer vaccine - immatics

Latest Information Update: 24 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator immatics biotechnologies GmbH
  • Class Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action CD4-positive T lymphocyte stimulants; CD8 positive T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal cell carcinoma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Renal cell carcinoma

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 03 May 2016 Discontinued - Phase-II for Renal cell carcinoma (Combination therapy, Late-stage disease, Second-line therapy or greater) in Spain, Switzerland, Slovakia, Bulgaria, Austria (Intradermal) (Immatics pipeline, May 2016)
  • 03 May 2016 Discontinued - Phase-III for Renal cell carcinoma (Combination therapy, First-line therapy, Late-stage disease) in Germany, USA, France, Hungary, Italy, Netherlands, Norway, Poland, Romania, Russia, United Kingdom (Intradermal) (Immatics pipeline, May 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top